Q1 Earnings Estimate for CRDF Issued By William Blair

Cardiff Oncology, Inc. (NASDAQ:CRDF) – William Blair issued their Q1 2026 EPS estimates for Cardiff Oncology in a report released on Thursday, February 27th. William Blair analyst A. Hsieh forecasts that the company will earn ($0.26) per share for the quarter. The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.99) per share. William Blair also issued estimates for Cardiff Oncology’s Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.28) EPS and Q4 2026 earnings at ($0.28) EPS.

A number of other equities research analysts have also issued reports on CRDF. HC Wainwright increased their price target on Cardiff Oncology from $13.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday. Piper Sandler increased their target price on Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th.

Cardiff Oncology Stock Performance

CRDF opened at $4.24 on Monday. Cardiff Oncology has a fifty-two week low of $2.01 and a fifty-two week high of $6.42. The firm’s fifty day moving average is $4.06 and its 200 day moving average is $3.24. The stock has a market cap of $216.81 million, a price-to-earnings ratio of -4.51 and a beta of 1.77.

Insider Buying and Selling

In related news, Director Gary W. Pace purchased 350,115 shares of Cardiff Oncology stock in a transaction on Wednesday, December 11th. The shares were bought at an average cost of $2.60 per share, for a total transaction of $910,299.00. Following the acquisition, the director now owns 1,047,876 shares in the company, valued at approximately $2,724,477.60. The trade was a 50.18 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 7.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new stake in shares of Cardiff Oncology in the fourth quarter worth about $25,000. ProShare Advisors LLC bought a new stake in Cardiff Oncology in the 4th quarter worth approximately $50,000. Raymond James Financial Inc. bought a new stake in Cardiff Oncology in the 4th quarter worth approximately $56,000. Voya Investment Management LLC purchased a new stake in shares of Cardiff Oncology during the 4th quarter worth approximately $57,000. Finally, Caxton Corp bought a new position in shares of Cardiff Oncology during the 4th quarter valued at approximately $58,000. Hedge funds and other institutional investors own 16.29% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.